drugset / Trial / NCT04294160
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2024-09-25
- Completion
- 2024-09-25
Outcome
Outcome not reported
Stopped (Business): “The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BATOPROTAFIB | Small molecule | — | Oral |
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | LTT462 | Unknown | — | Oral |
| Subject | Naporafenib | Small molecule | — | Oral |
| Subject | Spartalizumab | Monoclonal antibody | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trametinib | Small molecule | — | Oral |